Riikka Johanna Niemi1, Antti N Roine, Merja R Häkkinen, Pekka S Kumpulainen, Tuomo A Keinänen, Jouko J Vepsäläinen, Terho Lehtimäki, Niku K Oksala, Johanna U Mäenpää. 1. *Department of Obstetrics and Gynecology, Tampere University Hospital; †Faculty of Medicine and Life Sciences, University of Tampere, Tampere; ‡School of Pharmacy, Biocenter Kuopio, University of Eastern Finland, Kuopio; §Digital Health Solutions; ∥Department of Clinical Chemistry, Fimlab Laboratories and Faculty of Medicine and Life Sciences; ¶Department of Surgery, Faculty of Medicine and Life Sciences, University of Tampere; #Department of Vascular Surgery, Tampere University Hospital; and **Department of Obstetrics and Gynecology, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Abstract
OBJECTIVES: Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography-tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women. MATERIALS AND METHODS: In this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group. RESULTS: Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinary N,N-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors. N,N-diacetylspermine was elevated in malignant versus benign tumors (P < 0.001), in high-grade versus low malignant potential tumors (P < 0.001), in stage III to IV versus stage I to II cancers (P < 0.001), and even in early-stage cancer (stage I-II) versus benign tumors (P = 0.017). N,N-diacetylspermine had better sensitivity (86.5%) but lower specificity (65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%). CONCLUSIONS: Urinary N,N-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.
OBJECTIVES: Elevated concentrations of polyamines have been found in urine of patients with malignant tumors, including ovarian cancer. Previous research has suffered from poorly standardized detection methods. Our liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is capable of simultaneous standardized analysis of most known polyamines. Liquid chromatography-tandem mass spectrometry has not previously been used in the differential diagnostics of ovarian tumors in postmenopausal women. MATERIALS AND METHODS: In this prospective study, postmenopausal women (n = 71) presenting with an adnexal mass and, as controls, women with genital prolapse or urinary incontinence scheduled for surgery (n = 22) were recruited in the study. For analysis of the polyamines, a morning urine sample was obtained before surgery. Preoperative serum CA125 concentrations were determined in the study group. RESULTS: Twenty-three women with benign and 37 with malignant ovarian tumors were eligible. Of all analyzed polyamines, only urinary N,N-diacetylspermine showed statistically significant differences between all groups except controls versus benign tumors. N,N-diacetylspermine was elevated in malignant versus benign tumors (P < 0.001), in high-grade versus low malignant potential tumors (P < 0.001), in stage III to IV versus stage I to II cancers (P < 0.001), and even in early-stage cancer (stage I-II) versus benign tumors (P = 0.017). N,N-diacetylspermine had better sensitivity (86.5%) but lower specificity (65.2%) for distinguishing benign and malignant ovarian tumors than CA125 with a cut-off value of 35 kU/L (sensitivity, 75.7%; specificity, 69.6%). CONCLUSIONS: Urinary N,N-diacetylspermine seems to be able to distinguish benign and malignant ovarian tumors as well as early and advanced stage, and low malignant potential and high-grade ovarian cancers from each other, respectively.
Authors: Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann Journal: Chem Rev Date: 2022-01-07 Impact factor: 60.622
Authors: Johannes F Fahrmann; Ehsan Irajizad; Makoto Kobayashi; Jody Vykoukal; Jennifer B Dennison; Eunice Murage; Ranran Wu; James P Long; Kim-Anh Do; Joseph Celestino; Karen H Lu; Zhen Lu; Robert C Bast; Samir Hanash Journal: Cancers (Basel) Date: 2021-02-22 Impact factor: 6.639
Authors: Samuli I Nissinen; Markus Venäläinen; Pekka Kumpulainen; Antti Roine; Merja R Häkkinen; Jouko Vepsäläinen; Niku Oksala; Tuomo Rantanen Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302
Authors: Panagiotis Giamougiannis; Camilo L M Morais; Brice Rodriguez; Nicholas J Wood; Pierre L Martin-Hirsch; Francis L Martin Journal: Anal Bioanal Chem Date: 2021-07-01 Impact factor: 4.142